All currencies in US Dollar
JemalASiegelRWardE. Cancer statistics, 2009. CA Cancer J Clin2009;59:225–229.
GreeneFPageDFlemingIFritzA. AJCC Cancer Staging Manual. New York: Springer-Verlag; 2002.
HemminkiKEngC. Clinical genetic counselling for familial cancers requires reliable data on familial cancer risks and general action plans. J Med Genet2004;41:801–807.
AhsanHNeugutAIGarbowskiGC. Family history of colorectal adenomatous polyps and increased risk for colorectal cancer. Ann Intern Med1998;128:900–905.
BonelliLMartinesHConioM. Family history of colorectal cancer as a risk factor for benign and malignant tumours of the large bowel. A case-control study. Int J Cancer1988;41:513–517.
ComptonCCGreeneFL. The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin2004;54:295–308.
O’ConnellJBMaggardMAKoCY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst2004;96:1420–1425.
BurkeHB. Outcome prediction and the future of the TNM staging system. J Natl Cancer Inst2004;96:1408–1409.
ComptonCC. Updated protocol for the examination of specimens from patients with carcinomas of the colon and rectum, excluding carcinoid tumors, lymphomas, sarcomas, and tumors of the vermiform appendix: a basis for checklists. Cancer Committee. Arch Pathol Lab Med2000;124:1016–1025.
ComptonCCFieldingLPBurgartLJ. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med2000;124:979–994.
GreeneFLStewartAKNortonHJ. A new TNM staging strategy for node-positive (stage III) colon cancer: an analysis of 50,042 patients. Ann Surg2002;236:416–421.
SobinLHGreeneFL. TNM classification. Clarification of number of regional lymph nodes for pN0. Cancer2001;92:452.
SarliLBaderGIuscoD. Number of lymph nodes examined and prognosis of TNM stage II colorectal cancer. Eur J Cancer2005;41:272–279.
Le VoyerTSigurdsonEHamlinA. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol2003;21:2912–2919.
BilimoriaKPalisBStewartAK. Impact of tumor location on nodal evaluation for colon cancer. Dis Colon Rectum2008;51:154–161.
NewlandRCDentOFLyttleMN. Pathologic determinants of survival associated with colorectal cancer with lymph node metastases. A multivariate analysis of 579 patients. Cancer1994;73:2076–2082.
ChapuisPHDentOFBokeyEL. Adverse histopathological findings as a guide to patient management after curative resection of node-positive colonic cancer. Br J Surg2004;91:349–354.
WongSLHongJHollenbeckBK. Hospital lymph node examination rates and survival after resection for colon cancer. JAMA2007;298:2149–2154.
RedstonMComptonCCMiedemaBW. Analysis of micrometastatic disease in sentinel lymph nodes from resectable colon cancer: results of Cancer and Leukemia Group B trial 80001. J Clin Oncol2006;24:878–883.
SahaSVanABeutlerT. Sentinel lymph mapping techniques in colorectal cancer. Semin Oncol2004;31:374–381.
WieseDASahaSBadinJ. Pathologic evaluation of sentinel lymph nodes in colorectal carcinoma. Arch Pathol Lab Med2000;124:1759–1763.
BertagnolliMMiedemaBRedstonM. Sentinel node staging of resectable colon cancer: results of a multicenter study. Ann Surg2004;240:624–628; discussion 628–630.
NouraSYamamotoHMiyakeY. Immunohistochemical assessment of localization and frequency of micrometastases in lymph nodes of colorectal cancer. Clin Cancer Res2002;8:759–767.
BaselgaJRosenN. Determinants of RASistance to anti-epidermal growth factor receptor agents. J Clin Oncol2008;26:1582–1584.
AmadoRGWolfMPeetersM. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol2008;26:1626–1634.
Khambata-FordSGarrettCRMeropolNJ. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol2007;25:3230–3237.
De RoockWPiessevauxHDe SchutterJ. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol2008;19:508–515.
PuntCJTolJRodenburgCJ. Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract LBA 4011.
BokemeyerCBondarenkoIMakhsonA. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol2009;27:663–771.
TejparSPeetersMHumbletY. Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer, treated with irinotecan and escalating doses of cetuximab: the EVEREST experience (preliminary data) [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract 4001.
Van CutsemEHenning-KohneCHitreE. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med2009; 36014:1408–1417.
LièvreABachetJBBoigeV. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol2008;26:374–379.
KarapetisCSKhambata-FordSJonkerDJ. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med2008;359:1757–1765.
LievreABachetJ-BBoigeV. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treatment with cetuximab. J Clin Oncol2008;26:374–379.
ArtaleSSartore-BianchiAVeroneseSM. Mutations in KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol2008;26:4217–4219.
Etienne-GrimaldiMCFormentoJLFrancoualM. KRAS mutations in treatment outcome in colorectal cancer in patients receiving exclusive fluoropyrimidine. Clin Cancer Res2008;14:4830–4835.
CooperHSDeppischLMGourleyWK. Endoscopically removed malignant colorectal polyps: clinicopathologic correlations. Gastroenterology1995;108:1657–1665.
MarkowitzAJWinawerSJ. Management of colorectal polyps. CA Cancer J Clin1997;47:93–112.
NivatvongsSRojanasakulAReimanHM. The risk of lymph node metastasis in colorectal polyps with invasive adenocarcinoma. Dis Colon Rectum1991;34:323–328.
VolkEEGoldblumJRPetrasRE. Management and outcome of patients with invasive carcinoma arising in colorectal polyps. Gastroenterology1995;109:1801–1807.
UenoHMochizukiHHashiguchiY. Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology2004;127:385–394.
SeitzUBohnackerSSeewaldS. Is endoscopic polypectomy an adequate therapy for malignant colorectal adenomas? Presentation of 114 patients and review of the literature. Dis Colon Rectum2004;47:1789–1796.
HaggittRCGlotzbachRESofferEEWrubleLD. Prognostic factors in colorectal carcinomas arising in adenomas: implications for lesions removed by endoscopic polypectomy. Gastroenterology1985;89:328–336.
CrawleyJPetrasRCareyW. When is endoscopic polypectomy adequate therapy for colonic polyps containing invasive cancer?Gastroenterology1986;91:419–427.
WinawerSJFletcherRHMillerL. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology1997;112:594–642.
BalthazarEJMegibowAJHulnickDNaidichDP. Carcinoma of the colon: detection and preoperative staging by CT. AJR Am J Roentgenol1988;150:301–306.
CohenAM. Surgical considerations in patients with cancer of the colon and rectum. Semin Oncol1991;18:381–387.
JosephNESigurdsonERHanlonAL. Accuracy of determining nodal negativity in colorectal cancer on the basis of the number of nodes retrieved on resection. Ann Surg Oncol2003;10:213–218.
BergerACSigurdsonERLeVoyerT. Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol2005;23:8706–8712.
JohnsonPMPorterGARicciardiRBaxterNN. Increasing negative lymph node count is independently associated with improved long-term survival in stage IIIB and IIIC colon cancer. J Clin Oncol2006;24:3570–3575.
LacyAMGarcia-ValdecasasJCDelgadoS. Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. Lancet2002;359:2224–2229.
BuunenMVeldkampRHopWC. Survival after laparoscopic surgery versus open surgery for colon cancer: long-term outcome of a randomised clinical trial. Lancet Oncol2009;10:44–52.
JayneDGGuillouThorpeH. Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC trial group. J Clin Oncol2007;25:3061–3068.
Clinical Outcomes of Surgical Therapy Study Group. A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med2004;350:2050–2059.
FleshmanJSargentDJGreenE. Laparoscopic colectomy for cancer is not inferior to open surgery based on 5-year data from the COST study group trial. Ann Surg2007;246:655–664.
KuhryESchwenkWGaupsetR. Long-term results of laparoscopic colorectal cancer resection. Cochrane Database Syst Rev2008;CD003432.
BonjerHJHopWCNelsonH. Laparoscopically assisted vs open colectomy for colon cancer: a meta-analysis. Arch Surg2007;142:298–303.
JacksonTDKaplanGGArenaG. Laparoscopic versus open resection for colorectal cancer: a metaanalysis of oncologic outcomes. J Am Coll Surg2007;204:439–446.
KuhryEBonjerHJHaglindE. Impact of hospital case volume on short-term outcome after laparoscopic operation for colonic cancer. Surg Endosc2005;19:687–692.
KienlePWeitzJKochMBuchlerMW. Laparoscopic surgery for colorectal cancer. Colorectal Dis2006;8(Suppl 3):33–36.
WagmanLJ. Laparoscopic and open surgery for colorectal cancer: reaching equipoise?J Clin Oncol2007;25:2996–2998.
WishnerJDBakerJWJrHoffmanGC. Laparoscopic-assisted colectomy. The learning curve. Surg Endosc1995;9:1179–1183.
NelsonHWeeksJCWieandHS. Proposed phase III trial comparing laparoscopic-assisted colectomy versus open colectomy for colon cancer. J Natl Cancer Inst Monogr1995;19:51–56.
OtaDNelsonHWeeksJ. Controversies regarding laparoscopic colectomy for malignant diseases. Curr Opin Gen Surg1994:208–213.
SunWHallerDG. Adjuvant therapy of colon cancer. Semin Oncol2005;32:95–102.
BaddiLBensonAIII. Adjuvant therapy in stage II colon cancer: current approaches. Oncologist2005;10:325–331.
BensonABIII. New approaches to the adjuvant therapy of colon cancer. Oncologist2006;11:973–980.
AndreTBoniCMounedji-BoudiafL. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med2004;350:2343–2351.
de GramontABoniCNavarroM. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: efficacy results with a median follow-up of 4 years [abstract]. J Clin Oncol2005;23(Suppl 1):Abstract 3501.
de GramontABoniCNavarroM. Oxaliplatin/5-FU/LV in adjuvant colon cancer: updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of 6 years [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 4007.
SargentDJWieandHSHallerDG. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol2005;23:8664–8670.
SargentDJ. Time-dependent patterns of failure and treatment benefit from adjuvant therapy for resectable colon cancer: lessons from the 20,800-patient ACCENT dataset [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 4008.
SargentDSobreroAGrotheyA. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol2009;27:872–877.
AndreTBoniCNavarroM. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol2009;27:3109–3116.
SaltzLNiedzwieckiDHollisD. Irinotecan fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol2007;25:3456–3461.
RothenbergMLMeropolNJPoplinEA. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol2001;19:3801–3807.
Van CutsemELabiancaRBodokyG. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol2009;27:3117–3125.
YchouMRaoulJLDouillardJY. A phase III randomized trial of LV5FU2 + CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol2009;20:674–680.
WolmarkNWieandHKueblerJ. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: results of NSABP Protocol C-07 [abstract]. J Clin Oncol2005;23(Suppl 1):Abstract 3500.
KueblerJPWieandSO’ConnellMJ. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol2007;25:2198–2204.
TwelvesCWongANowackiMP. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med2005;352:2696–2704.
Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet1995;345:939–944.
International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol1999;17:1356–1363.
GillSLoprinziCLSargentDJ. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?J Clin Oncol2004;22:1797–1806.
SchragDRifas-ShimanSSaltzL. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol2002;20:3999–4005.
WolmarkNRocketteHMamounasE. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes’ B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol1999;17:3553–3559.
HallerDGCatalanoPJMacdonaldJS. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol2005;23:8671–8678.
Quasar Collaborative GroupGrayRBarnwellJMcConkeyC. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet2007;370:2020–2029.
BensonABIIISchragDSomerfieldMR. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol2004;22:3408–3419.
LoveNBylundCMeropolNJ. How well do we communicate with patients concerning adjuvant systemic therapy? A survey of 150 colorectal cancer survivors [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 4200.
HongTSRitterMATomeWAHarariPM. Intensity-modulated radiation therapy: emerging cancer treatment technology. Br J Cancer2005;92:1819–1824.
BensonABIII. New approaches to assessing and treating early-stage colon and rectal cancers: cooperative group strategies for assessing optimal appro0aches in early-stage disease. Clin Cancer Res2007;13:6913s–6920s.
Van CutsemENordlingerBAdamR. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer2006;42:2212–2221.
YooPSLopez-SolerRILongoWEChaCH. Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab. Clin Colorectal Cancer2006;6:202–207.
KemenyN. Management of liver metastases from colorectal cancer. Oncology (Williston Park)2006;20:1161–11761179; discussion 1179–1180 1185–1166.
MuratoreAZorziDBouzariH. Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy?Ann Surg Oncol2007;14:766–770.
AlbertsSRHorvathWLSternfeldWC. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol2005;23:9243–9249.
FongYCohenAMFortnerJG. Liver resection for colorectal metastases. J Clin Oncol1997;15:938–946.
TsaiMSuYHoM. Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastases. Ann Surg Oncol2007;14:786–794.
PoultsidesGAServaisELSaltzLB. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol2009;27:3379–3384.
FosterJH. Treatment of metastatic disease of the liver: a skeptic’s view. Semin Liver Dis1984;4:170–179.
StanglRAltendorf-HofmannACharnleyRMScheeleJ.. Factors influencing the natural history of colorectal liver metastases. Lancet1994;343:1405–1410.
VenookAP. The Kemeny article reviewed. Oncology2006;20:477–484.
ChotiMASitzmannJVTiburiMF. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg2002;235:759–766.
PawlikTMScogginsCRZorziD. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg2005;241:715–722.
CharnsangavejCClaryBFongY. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol2006;13:1261–1268.
VautheyJNZorziDPawlikTM. Making unresectable hepatic colorectal metastases resectable--does it work?Semin Oncol2005;32(Suppl 9):S118–122.
PozzoCBassoMCassanoA. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol2004;15:933–939.
Altendorf-HofmannAScheeleJ. A critical review of the major indicators of prognosis after resection of hepatic metastases from colorectal carcinoma. Surg Oncol Clin N Am2003;12:165–192.
PawlikTMSchulickRDChotiMA. Expanding criteria for resectability of colorectal liver metastases. Oncologist2008;13:51–64.
FolprechtGGrotheyAAlbertsS. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol2005;16:1311–1319.
ReddySKPawlikTMZorziD. Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann Surg Oncol2007;14:3481–3491.
CoveyAMBrownKTJarnaginWR. Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases. Ann Surg2008;247:451–455.
AdamRMillerRPitomboM. Two-stage hepatectomy approach for initially unresectable colorectal hepatic metastases. Surg Oncol Clin N Am2007;16:525–536.
AbdallaEK. Commentary: radiofrequency ablation for colorectal liver metastases: do not blame the biology when it is the technology. Am J Surg2009;197:737–739.
AbdallaEKVautheyJNEllisLM. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg2004;239:818–825.
HurHKoYTMinBS. Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. Am J Surg2009;197:728–736.
GleisnerALChotiMAAssumpcaoL. Colorectal liver metastases: recurrence and survival following hepatic resectin, radiofrequency ablation, and combined resection-radiofrequency ablation. Arch Surg2008;143:1204–1212.
ReuterNPWoodallCEScogginsCR. Radiofrequency ablation vs. resection for hepatic colorectal metastasis: therapeutically equivalent?J Gastrointest Surg2009;13:486–491.
BilchikAJPostonGAdamRChotiMA. Prognostic variables for resection of colorectal cancer hepatic metastases: an evolving paradigm. J Clin Oncol2008;26:5320–5321.
LeonardGDBrennerBKemenyNE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol2005;23:2038–2048.
BenoistSBrouquetAPennaC. Complete response of colorectal liver metastases after chemotherapy: does it mean cure?J Clin Oncol2006;24:3939–3945.
BilchikAJPostonGCurleySA. Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. J Clin Oncol2005;23:9073–9078.
AdamRAvisarEAricheA. Five-year survival following hepatic resecton after neoadjuvant therapy for nonresectable colorectal cancer. Ann Surg Oncol2001;8:347–353.
RivoireMDe CianFMeeusP. Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma. Cancer2002;95:2283–2292.
VautheyJNPawlikTMRiberoD. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol2006;24:2065–2072.
PawlikTMOlinoKGleisnerAL. Preoperative chemotheapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg2007;11:860–888.
PawlikTMPoonRTAbdallaEK. Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg2005;140:450–457; discussion 457–458.
EliasDLiberaleGVernereyD. Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol2005;12:900–909.
FongYSaloJ. Surgical therapy of hepatic colorectal metastasis. Semin Oncol1999;26:514–523.
AdamRDelvartVPascalG. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg2004;240:644–657.
DelaunoitTAlbertsSRSargentDJ. Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann Oncol2005;16:425–429.
NordlingerBSorbyeHGlimeliusB. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomized controlled trial. Lancet2008;37:1007–1016.
TanBRZubalBHawkinsw. Preoperative FOLFOX plus cetuximab or panitumumab therapy for patients with potentially resectable hepatic colorectal metastases. Gastrointestinal Cancers Symposium2009; Abstract 497.
FolprechtGGruenbergerTHartmannJT. Cetuximab plus FOLFOX6 or cetuximab plus FOLFIRI as neoadjuvant treatment of nonresectable colorectal liver metastases: a randomized multicenter study (CELIM-study) [abstract]. Presented at the 2009 ASCO Gastrointestinal Cancers Symposium; January 15–17, 2009; San Francisco, California. Abstract 296.
SouglakosJAndroulakisNSyrigosK. FOLFOXIRI vs FOLFIRI as first-line treatment in metastatic colorectal cancer: a multicentre randomised phase III trial from the Hellenic Oncology Research Group. Br J Cancer2006;94:798–805.
FalconeARicciSBrunettiI. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol2007;25:1670–1676.
ScappaticciFAFehrenbacherLCartwrightT. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol2005;91:173–180.
Package Insert. Bevacizumab (Avastin®). South San Francisco, CAGenentech, Inc.October2006.
GruenbergerBTamandlDSchuellerJ. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol2008;26:1830–1835.
ReddySKMorseMAHurwitzHI. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg2008;206:96–106.
Rubbia-BrandtLAudardVSartorettiP. Severe hepatic sinusoidal obstructjion associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol2004;15:460–466.
ZorziDKishiYMaruDM. Effect of extended preoperative chemotherapy on pathologic response and postoperative liver insufficiency after hepatic resection for colorectal liver metastases [abstract]. Presented at the 2009 ASCO Gastrointestinal Cancers Symposium; January 15–17, 2009; San Francisco, California. Abstract 295.
LeeWSYunSHChunHK. Pulmonary resection for metastases from colorectal cancer: prognostic factors and survival. Int J Colorectal Dis2007;22:699–704.
HeadrickJRMillerDLNagorneyDM. Surgical treatment of hepatic and pulmonary metastases from colon cancer. Ann Thorac Surg2001;71:975–979; discussion 979–980.
MitryEFieldsALABleibergH. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol2008;26:4906–4911.
KemenyNHuangYCohenAM. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med1999;341:2039–2048.
KemenyNEGonenM. Hepatic arterial infusion after liver resection. N Engl J Med2005;352:734–735.
MulcahyMFLewandowskiRJIbrahimSM. Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. Cancer2009;115:1849–1858.
HongKMcBrideJDGeorgiadesCS. Salvage therapy for liver-dominant colorectal metastatic adenocarcinoma: comparison between transcatheter arterial chemoembolization versus yttrium-90 radioembolization. J Vasc Interv Radiol2009;20:360–367.
KatzAWCarey-SampsonMMuhsAG. Hypofractionated stereotactic body radiation therapy (SBRT) for patients with limited hepatic metastases. Int J Radiat Oncol Biol Phys2007;67:793–798.
DelbekeDMartinWH. PET and PET-CT for evaluation of colorectal carcinoma. Semin Nucl Med2004;34:209–223.
BartlettDLBerlinJLauwersGY. Chemotherapy and regional therapy of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol2006;13:1284–1292.
YanTDBlackDSavadyRSugarbakerPH. Systemic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol2006;24:4011–4019.
EsquivelJSticcaRSugarbakerP. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol2007;14:128–133.
PelosiEDeandreisD. The role of 18F-fluoro-deoxy-glucose positron emission tomography (FDG-PET) in the management of patients with colorectal cancer. Eur J Surg Oncol2007;33:1–6.
KellyHGoldbergRM. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol2005;23:4553–4560.
GoldbergRM. Therapy for metastatic colorectal cancer. Oncologist2006;11:981–987.
GoldbergRMRothenbergMLVan CutsemE. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist2007;12:38–50.
GoldbergRMSargentDJMortonRF. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. J Clin Oncol2006;24:3347–3353.
DouillardJYCunninghamDRothAD. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet2000;355:1041–1047.
FuchsCSMooreMRHarkerG. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol2003;21:807–814.
PetrelliNHerreraLRustumY. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol1987;5:1559–1565.
Van CutsemETwelvesCCassidyJ. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol2001;19:4097–4106.
Van CutsemEHoffPMHarperP. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer2004;90:1190–1197.
BurokerTRO’ConnellMJWieandHS. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol1994;12:14–20.
de GramontABossetJFMilanC. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol1997;15:808–815.
Maindrault-GoebelFLouvetCAndreT. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer1999;35:1338–1342.
Van CutsemEPeetersMSienaS. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol2007;25:1658–1664.
CunninghamDHumbletYSienaS. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med2004;351:337–345.
van CutsemE. Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer. Oncologist2006;11:1010–1017.
RaymondEFaivreSWoynarowskiJMChaneySG. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol1998;25(Suppl 5):4–12.
O’DwyerPJ. The present and future of angiogenesis-directed treatments of colorectal cancer. Oncologist2006;11:992–998.
LentzFTranAReyE. Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications. Am J Pharmacogenomics2005;5:21–33.
RothenbergMLBlankeCD. Topoisomerase I inhibitors in the treatment of colorectal cancer. Semin Oncol1999;26:632–639.
GoldbergRMSargentDJMortonRF. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol2004;22:23–30.
TournigandCAndreTAchilleE. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol2004;22:229–237.
DelaunoitTGoldbergRMSargentDJ. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741. Cancer2004;101:2170–2176.
CheesemanSLJoelSPChesterJD. A ‘modified de Gramont’ regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer2002;87:393–399.
de GramontAFigerASeymourM. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol2000;18:2938–2947.
ColucciGGebbiaVPaolettiG. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol2005;23:4866–4875.
CassidyJClarkeSDiaz-RubioD. XELOX vs. FOLFOX4: efficacy results from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer [abstract]. Presented at the 2007 ASCO Gastrointestinal Cancers Symposium; January 19–21, 2007; Orlando Florida. Abstract 270.
CassidyJTaberneroJTwelvesC. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol2004;22:2084–2091.
PorschenRArkenauHTKubickaS. Phase III study of capecitabine plus oxaliplatin compared with fluororuracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol2007;25:4217–4223.
AndreTLouvetCMaindrault-GoebelF. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer1999;35:1343–1347.
JagerEHeikeMBernhardH. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. J Clin Oncol1996;14:2274–2279.
WolmarkNRocketteHFisherB. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol1993;11:1879–1887.
SaltzLBClarkeSDíaz-RubioE. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol2008;26:2013–2039.
SaltzLBClarkeSDiaz-RubioE. Bevacizumab in combination with XELOX or FOLFOX4: efficacy results from XELOX-1/NO16966, a randomized phase III trial in the first-line treatment of metastatic colorectal cancer [abstract]. Presented at the 2007 ASCO Gastrointestinal Cancers Symposium; January 19–21, 2007; Orlando Florida. Abstract 238.
KabbinavarFFSchulzJMcCleodM. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol2005;23:3697–3705.
HurwitzHIFehrenbacherLHainsworthJD. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol2005;23:3502–3508.
HochsterHSHartLLRamanathanRK. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 2008;26:3523–3529. Erratum in: J Clin Oncol2008;26:4697.
KabbinavarFFHambletonJMassRD. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol2005;23:3706–3712.
HurwitzHFehrenbacherLNovotnyW. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med2004;350:2335–2342.
FuchsCSMarshallJMitchellEP. Updated results of BICC-C study comparing first-line irinotecan /fluoropyrimidine combinations +/- celecoxib in mCRC: clinical data cut-off September 1, 2006 [abstract]. Presented at the 2007 ASCO Gastrointestinal Cancers Symposium; January 19–21, 2007; Orlando Florida. Abstract 276.
FuchsCJMarshallJBarruecoJ. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J Clin Oncol2007;24:4779–4786.
SoberoAAcklandSCarrionR. Efficacy and safety of bevacizumab in combination with irinotecan and infusional 5-FU as first-line treatment for patients with metastatic colorectal cancer [abstract]. J Clin Oncol2006;24(Suppl 1):Abstract 3544.
GiantonioBCatalanoPMeropolN. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group study E3200. J Clin Oncol2007;25:1539–1544.
CannistraSAMatulonisUAPensonRT. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;25:5150–5152.
Package insert. Capecitabine (Xeloda®)Nutley, NJRoche Laboratories Inc.June2005.
HallerDGCassidyJClarkeSJ. Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol2008;26:2118–2123.
SchmollHJArnoldD. Update on capecitabine in colorectal cancer. Oncologist2006;11:1003–1009.
Package Insert. Irinotecan hydrochloride injection (Camptosar®)New York, NYPfizerJune2006.
InnocentiFUndeviaSDIyerL. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol2004;22:1382–1388.
LabCorp Capsule. UGT1A1 irinotecan toxicity. Managing medication dosing and predicting response to treatment of cancer with irinotecan (Camptosar CPT-11). 2006. Available at www.lapcorp.com.
O’DwyerPJCatalanoRB. Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J Clin Oncol2006;24:4534–4538.
Package insert. Oxaliplatin (Eloxatin®)Bedford, OH. Ben Venue LaboratoriesNovember2004.
TournigandCCervantesAFigerA. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer—a GERCOR study. J Clin Oncol2006;24:394–400.
Maindrault-GoebelFLledoGGhibaudelB. Final results for OPTIMOX-2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals after FOLFOX in patients with metastatic colorectal cancer: a GERCOR study [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 4013.
GrotheyASargentDGoldbergRMSchmollHJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol2004;22:1209–1214.
CunninghamDPyrhonenSJamesRD. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet1998;352:1413–1418.
RougierPVan CutsemEBajettaE. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet1998;352:1407–1412.
PitotHRowlandKSargentDJ. N9841: a randomized phase III equivalence trial of irinotecan (CPT-11) versus oxaliplatin/5-fluorouracil (5FU)/leucovorin (FOLFOX4) in patients (pts) with advanced colorectal cancer (CRC) previously treated with 5FU [abstract]. J Clin Oncol2005;23(Suppl 1):Abstract 3506.
SaltzLBMeropolNJLoehrerPJSr. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol2004;22:1201–1208.
SaltzLRubinMHochsterH. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR) [abstract]. Proc Am Soc Clin Oncol2001;20:Abstract 7.
JonkerDJO’CallaghanCJKarapetisCS. Cetuximab for the treatment of colorectal cancer. J Clin Oncol2007;357:2040–2047.
SobreroAFMaurelJFehrenbacherL. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol2008;26:2311–2319.
HechtJRMitchellEChidiacT. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol2009;27:672–680.
Package Insert. Cetuximab (Erbitux®)Branchburg, NJImclone Systems, Inc.2004.
Package Insert. Panitumumab (Vectibix™)Thousand Oaks, CAAmgenSeptember2006.
HelblingDBornerM. Successful challenge with the fully human EGFR antibody panitumumab following an infusion reaction with the chimeric EGFR antibody cetuximab. Ann Oncol2007;18:963–964.
HeunJHolenK. Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: a case report. Clin Colorectal Cancer2007;6:529–531.
BerlinJvan CutsemEPeetersM. Predictive value of skin toxicity severity for response to panitumumab in pateints with metastatic colorectal cancer: a pooled analysis of five clinical trials [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 4134.
HechtJRMitchellEChidiacT. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol2009;27:672–680.
TolJKoopmanMCatsA. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med2009;360:563–572.
HechtJMitchellEBarandaJ. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing low (1-9%) or negative (<1%) levels of epidermal growth receptor (EGFr) [abstract]. J Clin Oncol2006;24(Suppl 1):Abstract 3506.
GoldbergRMKohneGHSeymourMT. A pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials of 6,286 patients with metastatic colorectal cancer [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 4011.
HoffPMPazdurRLassereY. Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma. J Clin Oncol2004;22:2078–2083.
PietraNSarliLCostiR. Role of follow-up in management of local recurrences of colorectal cancer: a prospective, randomized study. Dis Colon Rectum1998;41:1127–1133.
SeccoGBFardelliRGianquintoD. Efficacy and cost of risk-adapted follow-up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. Eur J Surg Oncol2002;28:418–423.
Rodriguez-MorantaFSaloJArcusaA. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. J Clin Oncol2006;24:386–393.
FigueredoACharetteMLMarounJ. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care’s gastrointestinal cancer disease site group. J Clin Oncol2004;22:3395–3407.
RenehanAGEggerMSaundersMPO’DwyerST. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ2002;324:813.
JefferyMHickeyBHiderP. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev2007:CD002200.
DeschCEBensonABIIISomerfieldMR. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol2005;23:8512–8519.
GuyotFFaivreJManfrediS. Time trends in the treatment and survival of recurrences from colorectal cancer. Ann Oncol2005;16:756–761.
Li DestriGDi CataldoAPuleoS. Colorectal cancer follow-up: useful or useless?Surg Oncol2006;15:1–12.
PfisterDGBensonABIIISomerfieldMR. Clinical practice. Surveillance strategies after curative treatment of colorectal cancer. N Engl J Med2004;350:2375–2382.
LockerGYHamiltonSHarrisJ. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol2006;24:5313–5327.
RexDKKahiCJLevinB. Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and US Multi-Society Task Force on Colorectal Cancer. CA Cancer J Clin2006;56:160–167.
GreenRJMetlayJPPropertK. Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089. Ann Intern Med2002;136:261–269.
SprangersMAGTaalBGAaronsonNK. Quality of life in colorectal cancer: stoma vs. nonstoma patients. Dis Colon Rectum1995;38:361–369.
DenlingerCSBarsevickAM. The Challenges of Colorectal Cancer Survivorship. J Natl Compr Cancer Netw2009; in press.
DignamJLPoliteBNYothersG. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst2006;98:1647–1654.
MeyerhardtJAHeseltineDNiedzwieckiD. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol2006;24:3535–3541.
MeyerhardtJANiedzwieckiDHollisD. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA2007;298:754–764.
MartinEWJr.MintonJPCareyLC. CEA-directed second-look surgery in the asymptomatic patient after primary resection of colorectal carcinoma. Ann Surg1985;202:310–317.
All Time | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 0 | 0 | 0 |
Full Text Views | 801 | 801 | 171 |
PDF Downloads | 320 | 320 | 74 |
EPUB Downloads | 0 | 0 | 0 |